Training Programs

Cancer Biology

Potential Preceptors, Departmental Affiliation & Research
Department of Biochemistry and Molecular Biology
  • Millie M Georgiadis, Ph.D.: Macromolecular crystallography of nucleic acid interactions with proteins involved in replication, repair, transcriptional regulation, and recombination.
  • Thomas D. Hurley, Ph.D.: better elucidate the roles of aldehyde dehydrogenase isoenzymes in tumor resistance to oxazophoshorines, such as Cytoxan
  • Amber L. Mosley, Ph.D.: focused on the interplay between RNA Polymerase II transcription and chromatin. Proper regulation of RNA Polymerase II (RNAPII) transcription is essential for accurate gene expression and genome stability
  • Lawrence Quilliam, Ph.D.: Signaling via Ras, protein kinases and SH2/SH3 adaptor molecules in cancer.
  • Clark D. Wells, Ph.D.: to understand how de-differentiation of mammary epithelial cells during breast cancer initiation and progression is coordinated with the loss of growth control.
  • Zhong-Yin Zhang, Ph.D.: Chemical biology, signaling mediated by tyrosine dephosphorylation, targeting protein tyrosine phosphatases for the treatment of cancer.
Department of Dermatology
  • Elliot Androphy, M.D.: Mechanism of human papillomavirus–induced malignancies. Development of novel antiviral drugs. Mechanism of p53 tumor suppression.
Department of Epidemiology
  • Jaili Han, Ph.D.: understanding the influence of genetic and environmental factors on the etiology and prevention of cancers.
  • Chunyan He, ScD: cancer epidemiology, molecular and genetic epidemiology, cancer genetic susceptibility, etiology, and prevention, specifically the relationship between genetic variation and cancer risk for future prevention
Department of Medicine
  • Asok Antony, M.D.: Folate Receptors and Folate Metabolism
  • Darron Brown, M.D.: Human papillomaviruses (HPV)
  • Sherif Farag, M.D., Ph.D., FRACP, FRCPA: a) Development novel approaches to hematopoietic stem cell transplantation, including safer approaches to alternate donor transplantation through depletion of alloreactive T cells, utilization of KIR mismatches between donor and recipient, harnessing Treg cells, and NKT cells. b) Development of novel agents and regimens for the treatment of multiple myeloma. This includes pre-clinical research of novel agents (drug development).
  • David A. Flockhart, M.D., Ph.D.: Clinical Pharmacogenomics.
  • Theresa Guise, M.D.: Effects of cancer and cancer treatment on skeleton.
  • Murray Korc, M.D.: Mouse models of pancreatic cancer. MicroRNA in pancreatic cancer. TGF-beta and EGFR in pancreatic cancer.
  • Daniela Matei, M.D.: PDGFR signaling in cancer. Mechanisms of metastasis in ovarian cancer.
  • Christie Orschell, Ph.D.: Stem cell biology in human and murine systems, including isolation, functional characterization, ex vivo expansion, and gene transfer.
  • David Roodman, M.D., Ph.D.: Role of bone cells in normal and pathologic conditions in particular myeloma.
  • Todd C. Skaar, Ph.D.: clinical pharmacology with an emphasis on breast cancer and endocrine therapies used to treat and prevent breast cancer
  • John Turchi, Ph.D.:  Repair of chemotherapy–induced DNA damage and DNA double strand break repair.
Department of Medical Sciences
  • Kenneth P. Nephew, Ph.D.: Breast and ovarian cancers; cancer epigenetics (DNA and histone methylations); steroid hormone action (estrogen receptor signaling)
  • Heather M. O’Hagan, Ph.D.: Understanding of the mechanism and molecular progression of inflammation-induced epigenetic changes to be able to develop treatments that reverse these epigenetic changes after exposure and therefore prevent disease formation
Department of Microbiology and Immunology
  • Janice S. Blum, Ph.D.: Immune regulation, autoimmunity, biodefense, HLA, tumor and viral immunity, vaccines.
  • Hal E. Broxmeyer, Ph.D.: Regulation of the self-renewal, survival, proliferation, differentiation and migration of hematopoietic, embryonic, and induced pluripotent stem cells, and hematopoietic progenitor cells, cytokine-cell interactions, intracellular signaling, in-vivo preclinical and clinical assessment, modulation by gene transfer/gene therapy.
  • Randy R. Brutkiewicz, Ph.D.: Inhibition of anti-tumor immunity by invariant natural killer T cells and manipulation of these events through gene transfer.
  • Alexander L. Dent, Ph.D.: Growth and differentiation of lymphocytes
  • Mark H. Kaplan, Ph.D.: Stat4 immunobiology, modulation of immune cell reactivity and function by transcription factors such as Stat 3, 4 and 6.
  • Sophie Paczesny, M.D., Ph.D.: discovery and validation of biomarkers for complications post-transplant.
  • Louis M. Pelus, Ph.D.: The mechanisms by which bioactive cytokines and growth factors control cell proliferation, differentiation and migration, and how these pathways can be leveraged to define new therapeutics and new therapeutic applications.
Department of Orthopaedic Surgery
  • Melissa Kacena, Ph.D.: 1) understanding the role of osteoblasts in the hematopoietic stem cell niche. Specifically, to better understand the role of osteoblasts, bone marrow stromal cells, and megakaryocytes in expansion and longevity of hematopoietic stem cells. 2), study the role of Mdm2 and megakaryocytes in regulating tumor progression and metastasis in osteosarcoma.
Department of Pathology and Laboratory Medicine
Department of Pediatrics
  • Nadia Carlesso, M.D., Ph.D.: Understanding of hematopoietic stem cell biology and other molecular mechanisms to develop strategies for the manipulation of signaling pathways, as the Notch pathway, in the treatment of hematopoietic malignancies.
  • Rebecca Chan, M.D., Ph.D.: The functional and biochemical role of several of the observed Shp-2 molecules in murine hematopoietic progenitor cell growth and cytokine response.
  • D. Wade Clapp, M.D.: Biochemical and phenotypic effects of heterozygous inactivation of NF1, regulation of hematopoiesis and mast cell production, neurofibromatosis/NF1, gene transfer with retroviral, lentiviral and foamy viral vectors.
  • Reuben Kapur, Ph.D.: Molecular genetics of normal and leukemic stem/progenitor cells.
  • Mark R. Kelley, Ph.D.: Molecular and cellular biology and biochemistry of eukaryotic DNA base excision repair (BER) genes for basic science and translational applications to treat cancer and small molecule inhibitors of targeted DNA repair genes for anti-angiogenesis and tumor microenvironment therapies.
  • Lindsey Mayo, Ph.D.: to examine the regulation of tumor suppressors and oncogenes. 1. The factors involved the induction and regulation the activity of the Mdm2 oncogene in a breast model system of epithelial to mesenchymal transition (EMT).
  • Karen Pollok, Ph.D.: Modulation of DNA repair activity in hematopoietic stem and progenitor cells (HSPC) with a focus on in vivo models to study protection of HSC from chemotherapy.
  • Jamie L. Renbarger, M.D.: To Study the pharmacogenetics of anticancer agents. My current research focus is on the pharmacogenetics of the vinca alkaloids in children.
  • Jingwu Xie, Ph.D.: to investigate signal transduction of the hedgehog pathway and its role in the development of cancers.
Department of Pharmacology and Toxicology
  • Travis J. Jerde, Ph.D.: to understand how these signaling interactions promote epithelial proliferation and allow damaged cells to escape cell death in the inflamed prostate
  • Michael R. Vasko, Ph.D.: To determine the mechanisms mediating neurotoxicity secondary to cancer therapies including ionizing radiation and chemotherapy. Focus is on the role of oxidative damage and DNA repair on neurotoxicity which manifest as peripheral neuropathy and/or cognitive dysfunction.
  • Jian-Ting Zhang, Ph.D.: Drug resistance in chemotherapy, signal transduction, translational control and cancer. 
Department of Radiation Oncology
  • Joseph R. Dynlacht, Ph.D.: Elucidating the mechanisms of radiation-induced and heat-induced cell killing. Development of radiation countermeasures that may be useful for treatment of mass casualties following a radiological terrorism incident or criticality accident. Development of novel compounds that can be used as adjuvants to radiotherapy and thermal therapy (hyperthermia and thermal ablation). Development of agents that mitigate the side effects of radiotherapy.
Department of Radiology
Department of Surgery
School of Medicine 
  • Jay L. Hess M.D., Ph.D., M.H.S.A.: focused on the mechanisms of Hox gene regulation by the mixed lineage leukemia protein, MLL, transcriptional deregulation by MLL fusion proteins, and the role of Hox genes in hematopoiesis and leukemia. 
School of Nursing